Negative feedback regulation of the ERK1/2 MAPK pathway

David Lake, Sonia A L Corrêa, Jürgen Müller, David Lake, Sonia A L Corrêa, Jürgen Müller

Abstract

The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance.

Keywords: Cancer; Cell signalling; Negative feedback; Pathway modelling; Signalling dynamics; Spatiotemporal regulation.

Figures

Fig. 1
Fig. 1
Negative feedback regulation of the ERK1/2 MAPK pathway. The ERK1/2 MAPK pathway is subject to a large number of negative feedback loops. These include direct phosphorylation by ERK1/2 (and RSK2) as well as transcriptionally induced feedback regulators, such as DUSPs and Sprouty proteins. The major negative feedback loops acting on the ERK1/2 pathway are shown
Fig. 2
Fig. 2
ERK1/2 MAPK signalling in response to different oncogenic stimuli. a In cells with mutation or amplification of upstream components [e.g., RTKs (1)] and expressing wild-type Raf proteins, negative feedback mechanisms are highly active (2,3) and significantly reduce the activity of several upstream pathway components. This leads to relatively low (but still elevated) steady-state levels of MEK1/2 and ERK1/2 activity. When either Raf or MEK1/2 are inhibited, this negative feedback is reduced. As a result, signal flux is increased, restoring MEK1/2 and ERK1/2 activity and requiring significantly higher inhibitor doses (intrinsic resistance). Loss of negative feedback (2) due to pathway inhibition also results in increased Ras-GTP levels, which promotes the dimerisation of wild-type Raf proteins and results in the paradoxical promotion, rather than inhibition, of ERK1/2 signalling. Finally, the observed transcriptional output (4) of tumour cells with mutated RTKs or Ras is only partially driven by ERK1/2 activity because of the relatively small increase in the overall signalling flux due to extensive negative feedback. Inhibition of Raf or MEK1/2, therefore, does not sufficiently reduce the expression of those mitogenic genes to result in therapeutic changes. b Mutant B-Raf (5) is constitutively active and, therefore, not sensitive to direct feedback phosphorylation by ERK1/2 (6). In addition, as mutated B-Raf is independent of upstream activation, negative feedback to the upstream components has no effect on B-Raf activity (7). Because mutated B-Raf bypasses negative feedback, persistent hyperactivation of MEK1/2 (and ERK1/2) results in significantly increased transcriptional output of mitogenic genes (8). As mitogenic gene expression critically depends on high signalling flux through the pathway, those tumours are sensitive to the inhibition of MEK1/2 or B-Raf. In addition, the increased expression of DUSPs (9) in B-Raf mutant cells leads to the dephosphorylation of ERK1/2 and a reduction of its apparent activity to levels that support oncogenic transformation (rather than senescence). As a result, MEK1/2 (rather than ERK1/2) activity is a major hallmark and determinant of inhibitor selectivity (#)
Fig. 3
Fig. 3
Loss of negative feedback contributes to resistance to Raf and MEK1/2 inhibitors. Raf or MEK1/2 inhibition (1) results in lower levels of negative feedback to upstream components (2). As a result, the cell is returned to an RTK signalling-competent state, where Ras and other upstream factors are able to respond to signal activation (3). Therefore, signal flux is increased (4), promoting higher ERK1/2 activity and requiring higher inhibitor doses. The increased Ras activity can also activate parallel pathways, such as the PI3K/Akt pathway (5). In addition, loss of negative feedback leads to the de-repression of other RTK receptors (6), allowing different growth factors to activate downstream signalling pathways. Activation of the PI3K/Akt pathway can promote cell survival (7) and reduce the dependency of the tumour on ERK1/2 signalling, likely contributing to the acquired resistance to Raf and MEK1/2 inhibitors

References

    1. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007;26(22):3113–3121. doi: 10.1038/sj.onc.1210394.
    1. Gureasko J, Galush WJ, Boykevisch S, Sondermann H, Bar-Sagi D, Groves JT, Kuriyan J. Membrane-dependent signal integration by the Ras activator Son of sevenless. Nat Struct Mol Biol. 2008;15(5):452–461. doi: 10.1038/nsmb.1418.
    1. Chong H, Vikis HG, Guan K-L. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15(5):463–469. doi: 10.1016/S0898-6568(02)00139-0.
    1. Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281–298. doi: 10.1038/nrm3979.
    1. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res. 1999;253(1):34–46. doi: 10.1006/excr.1999.4689.
    1. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24(1):21–44. doi: 10.1080/02699050500284218.
    1. Northwood IC, Gonzalez FA, Wartmann M, Raden DL, Davis RJ. Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. J Biol Chem. 1991;266(23):15266–15276.
    1. Takishima K, Griswold-Prenner I, Ingebritsen T, Rosner MR. Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated “MAP” kinase. Proc Natl Acad Sci USA. 1991;88(6):2520–2524. doi: 10.1073/pnas.88.6.2520.
    1. Sato K, Shin M-S, Sakimura A, Zhou Y, Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I, Sakurai H. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci. 2013;104(10):1315–1322. doi: 10.1111/cas.12225.
    1. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72(13):3228–3237. doi: 10.1158/0008-5472.CAN-11-3747.
    1. Li X, Huang Y, Jiang J, Frank SJ. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal. 2008;20(11):2145–2155. doi: 10.1016/j.cellsig.2008.08.006.
    1. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009;315(4):683–696. doi: 10.1016/j.yexcr.2008.07.029.
    1. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–103. doi: 10.1038/nature10868.
    1. Zakrzewska M, Haugsten EM, Nadratowska-Wesolowska B, Oppelt A, Hausott B, Jin Y, Otlewski J, Wesche J, Wiedlocha A. ERK-mediated phosphorylation of fibroblast growth factor receptor 1 on Ser777 inhibits signaling. Sci Signal. 2013;6(262):ra11. doi: 10.1126/scisignal.2003087.
    1. Ueki K, Matsuda S, Tobe K, Gotoh Y, Tamemoto H, Yachi M, Akanuma Y, Yazaki Y, Nishida E, Kadowaki T. Feedback regulation of mitogen-activated protein kinase kinase kinase activity of c-Raf-1 by insulin and phorbol ester stimulation. J Biol Chem. 1994;269(22):15756–15761.
    1. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM. Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation. J Biol Chem. 1995;270(43):25320–25323. doi: 10.1074/jbc.270.43.25320.
    1. Corbalan-Garcia S, Yang SS, Degenhardt KR, Bar-Sagi D. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol Cell Biol. 1996;16(10):5674–5682. doi: 10.1128/MCB.16.10.5674.
    1. Porfiri E, McCormick F. Regulation of epidermal growth factor receptor signaling by phosphorylation of the Ras exchange factor hSOS1. J Biol Chem. 1996;271(10):5871–5877. doi: 10.1074/jbc.271.10.5871.
    1. Kamioka Y, Yasuda S, Fujita Y, Aoki K, Matsuda M. Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK. J Biol Chem. 2010;285(43):33540–33548. doi: 10.1074/jbc.M110.135517.
    1. Douville E, Downward J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene. 1997;15(4):373–383. doi: 10.1038/sj.onc.1201214.
    1. Saha M, Carriere A, Cheerathodi M, Zhang X, Lavoie G, Rush J, Roux PP, Ballif BA. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. Biochem J. 2012;447(1):159–166. doi: 10.1042/BJ20120938.
    1. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997;89(5):693–702. doi: 10.1016/S0092-8674(00)80252-4.
    1. Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J. The docking protein FRS2α controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell. 2002;10(4):709–719. doi: 10.1016/S1097-2765(02)00689-5.
    1. Wu Y, Chen Z, Ullrich A. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2. Biol Chem. 2003;384(8):1215–1226. doi: 10.1515/BC.2003.134.
    1. Fuller DM, Zhang W. Regulation of lymphocyte development and activation by the LAT family of adapter proteins. Immunol Rev. 2009;232(1):72–83. doi: 10.1111/j.1600-065X.2009.00828.x.
    1. Matsuda S, Miwa Y, Hirata Y, Minowa A, Tanaka J, Nishida E, Koyasu S. Negative feedback loop in T-cell activation through MAPK-catalyzed threonine phosphorylation of LAT. EMBO J. 2004;23(13):2577–2585. doi: 10.1038/sj.emboj.7600268.
    1. Hennig A, Markwart R, Wolff K, Schubert K, Cui Y, Prior IA, Esparza-Franco MA, Ladds G, Rubio I. Feedback activation of neurofibromin terminates growth factor-induced Ras activation. Cell Commun Signal. 2016;14(1):5. doi: 10.1186/s12964-016-0128-z.
    1. Wartmann M, Hofer P, Turowski P, Saltiel AR, Hynes NE. Negative modulation of membrane localization of the Raf-1 protein kinase by hyperphosphorylation. J Biol Chem. 1997;272(7):3915–3923. doi: 10.1074/jbc.272.7.3915.
    1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270(46):27489–27494. doi: 10.1074/jbc.270.46.27489.
    1. Weiss RH, Maga EA, Ramirez A. MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. Am J Physiol. 1998;274(6 Pt 1):C1521–C1529.
    1. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell. 2005;17(2):215–224. doi: 10.1016/j.molcel.2004.11.055.
    1. Müller J, Morrison DK. Assay of Raf-1 activity. Methods Enzymol. 2002;345:490–498. doi: 10.1016/S0076-6879(02)45040-9.
    1. Hekman M, Fischer A, Wennogle LP, Wang YK, Campbell SL, Rapp UR. Novel C-Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation. FEBS Lett. 2005;579(2):464–468. doi: 10.1016/j.febslet.2004.11.105.
    1. Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, Singh-Gupta V, Qin J, Ruan H, Comb MJ, Tzivion G. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell. 2006;17(3):1141–1153. doi: 10.1091/mbc.E04-12-1123.
    1. Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene. 2003;22(55):8823–8834. doi: 10.1038/sj.onc.1207185.
    1. Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol. 2010;30(3):806–819. doi: 10.1128/MCB.00569-09.
    1. Weber CK, Slupsky JR, Kalmes HA, Rapp UR. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 2001;61(9):3595–3598.
    1. Brunet A, Pagès G, Pouyssègur J. Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1) FEBS Lett. 1994;346(2–3):299–303.
    1. Coles LC, Shaw PE. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene. 2002;21(14):2236–2244. doi: 10.1038/sj.onc.1205302.
    1. Eblen ST, Slack-Davis JK, Tarcsafalvi A, Parsons JT, Weber MJ, Catling AD. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol. 2004;24(6):2308–2317. doi: 10.1128/MCB.24.6.2308-2317.2004.
    1. Rossomando AJ, Dent P, Sturgill TW, Marshak DR. Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation. Mol Cell Biol. 1994;14(3):1594–1602. doi: 10.1128/MCB.14.3.1594.
    1. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB, Marshall MS, Weber MJ, Parsons JT, Catling AD. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol. 2003;162(2):281–291. doi: 10.1083/jcb.200212141.
    1. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol. 2009;16(3):294–303. doi: 10.1038/nsmb.1564.
    1. Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal. 2009;21(4):462–469. doi: 10.1016/j.cellsig.2008.11.013.
    1. Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibáñez L, Marais R, Lewis RE, Berciano MT, Crespo P. Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol. 2009;29(5):1338–1353. doi: 10.1128/MCB.01359-08.
    1. Zeke A, Lukács M, Lim WA, Reményi A. Scaffolds: interaction platforms for cellular signalling circuits. Trends Cell Biol. 2009;19(8):364–374. doi: 10.1016/j.tcb.2009.05.007.
    1. Kornfeld K, Hom DB, Horvitz HR. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell. 1995;83(6):903–913. doi: 10.1016/0092-8674(95)90206-6.
    1. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. KSR, a novel protein kinase required for RAS signal transduction. Cell. 1995;83(6):879–888. doi: 10.1016/0092-8674(95)90204-X.
    1. Sundaram M, Han M. The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction. Cell. 1995;83(6):889–901. doi: 10.1016/0092-8674(95)90205-8.
    1. Denouel-Galy A, Douville EM, Warne PH, Papin C, Laugier D, Calothy G, Downward J, Eychène A. Murine Ksr interacts with MEK and inhibits Ras-induced transformation. Curr Biol CB. 1998;8(1):46–55. doi: 10.1016/S0960-9822(98)70019-3.
    1. Yu W, Fantl WJ, Harrowe G, Williams LT. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. Curr Biol CB. 1998;8(1):56–64. doi: 10.1016/S0960-9822(98)70020-X.
    1. Müller J, Ory S, Copeland T, Piwnica-Worms H, Morrison DK. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell. 2001;8(5):983–993. doi: 10.1016/S1097-2765(01)00383-5.
    1. Müller J, Ritt DA, Copeland TD, Morrison DK. Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate. EMBO J. 2003;22(17):4431–4442. doi: 10.1093/emboj/cdg426.
    1. Volle DJ, Fulton JA, Chaika OV, McDermott K, Huang H, Steinke LA, Lewis RE. Phosphorylation of the kinase suppressor of Ras by associated kinases†. Biochemistry. 1999;38(16):5130–5137. doi: 10.1021/bi983050d.
    1. Cacace AM, Michaud NR, Therrien M, Mathes K, Copeland T, Rubin GM, Morrison DK. Identification of constitutive and Ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. Mol Cell Biol. 1999;19(1):229–240. doi: 10.1128/MCB.19.1.229.
    1. Canal F, Palygin O, Pankratov Y, Corrêa SAL, Müller J. Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons. FASEB J. 2011;25(7):2362–2372. doi: 10.1096/fj.10-173153.
    1. McKay MM, Ritt DA, Morrison DK. Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci. 2009;106(27):11022–11027. doi: 10.1073/pnas.0901590106.
    1. Müller J, Cacace AM, Lyons WE, McGill CB, Morrison DK. Identification of B-KSR1, a novel brain-specific isoform of KSR1 that functions in neuronal signaling. Mol Cell Biol. 2000;20(15):5529–5539. doi: 10.1128/MCB.20.15.5529-5539.2000.
    1. Shalin SC, Hernandez CM, Dougherty MK, Morrison DK, Sweatt JD. Kinase suppressor of Ras1 compartmentalizes hippocampal signal transduction and subserves synaptic plasticity and memory formation. Neuron. 2006;50(5):765–779. doi: 10.1016/j.neuron.2006.04.029.
    1. Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol. 2000;12(2):186–192. doi: 10.1016/S0955-0674(99)00075-7.
    1. Caunt CJ, Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) FEBS J. 2013;280(2):489–504. doi: 10.1111/j.1742-4658.2012.08716.x.
    1. Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012;2(1):24. doi: 10.1186/2045-3701-2-24.
    1. Ekerot M, Stavridis MP, Delavaine L, Mitchell MP, Staples C, Owens DM, Keenan ID, Dickinson RJ, Storey KG, Keyse SM. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J. 2008;412(2):287–298. doi: 10.1042/BJ20071512.
    1. Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, LaFramboise T, Levine AD, Halmos B. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis. 2010;31(4):577–586. doi: 10.1093/carcin/bgq020.
    1. Karlsson M, Mathers J, Dickinson RJ, Mandl M, Keyse SM. Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal. J Biol Chem. 2004;279(40):41882–41891. doi: 10.1074/jbc.M406720200.
    1. Mandl M, Slack DN, Keyse SM. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol. 2005;25(5):1830–1845. doi: 10.1128/MCB.25.5.1830-1845.2005.
    1. Guy GR, Jackson RA, Yusoff P, Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol. 2009;203(2):191–202. doi: 10.1677/JOE-09-0110.
    1. Casci T, Vinós J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 1999;96(5):655–665. doi: 10.1016/S0092-8674(00)80576-0.
    1. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the drosophila airways. Cell. 1998;92(2):253–263. doi: 10.1016/S0092-8674(00)80919-8.
    1. Kramer S, Okabe M, Hacohen N, Krasnow MA, Hiromi Y. Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. Development. 1999;126(11):2515–2525.
    1. Ozaki K, Kadomoto R, Asato K, Tanimura S, Itoh N, Kohno M. ERK pathway positively regulates the expression of sprouty genes. Biochem Biophys Res Commun. 2001;285(5):1084–1088. doi: 10.1006/bbrc.2001.5295.
    1. Panagiotaki N, Dajas-Bailador F, Amaya E, Papalopulu N, Dorey K. Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo. Development. 2010;137(23):4005–4015. doi: 10.1242/dev.053173.
    1. Haimov-Kochman R, Ravhon A, Prus D, Greenfield C, Finci-Yeheskel Z, S Goldman-Wohl D, Natanson-Yaron S, Reich R, Yagel S, Hurwitz A. Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Mol Hum Reprod. 2005;11(8):537–542. doi: 10.1093/molehr/gah203.
    1. Yang X, Webster JB, Kovalenko D, Nadeau RJ, Zubanova O, Chen PY, Friesel R. Sprouty genes are expressed in osteoblasts and inhibit fibroblast growth factor-mediated osteoblast responses. Calcif Tissue Int. 2006;78(4):233–240. doi: 10.1007/s00223-005-0231-4.
    1. Sylvestersen KB, Herrera PL, Serup P, Rescan C. Fgf9 signalling stimulates Spred and Sprouty expression in embryonic mouse pancreas mesenchyme. Gene Expr Patterns. 2011;11(1–2):105–111. doi: 10.1016/j.gep.2010.10.001.
    1. Jiang ZL, Ripamonte P, Buratini J, Portela VM, Price CA. Fibroblast growth factor-2 regulation of sprouty and NR4A genes in bovine ovarian granulosa cells. J Cell Physiol. 2011;226(7):1820–1827. doi: 10.1002/jcp.22509.
    1. Mason JM, Morrison DJ, Albert Basson M, Licht JD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol. 2006;16(1):45–54. doi: 10.1016/j.tcb.2005.11.004.
    1. Hanafusa H, Torii S, Yasunaga T, Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol. 2002;4(11):850–858. doi: 10.1038/ncb867.
    1. Yusoff P, Lao D-H, Ong SH, Wong ESM, Lim J, Lo TL, Leong HF, Fong CW, Guy GR. Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem. 2002;277(5):3195–3201. doi: 10.1074/jbc.M108368200.
    1. Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol. 2003;5(5):427–432. doi: 10.1038/ncb978.
    1. Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. Cancer Metastasis Rev. 2014;33(2–3):695–720. doi: 10.1007/s10555-014-9497-1.
    1. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J. 1992;288:351–355. doi: 10.1042/bj2880351.
    1. Brightman FA, Fell DA. Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells. FEBS Lett. 2000;482(3):169–174. doi: 10.1016/S0014-5793(00)02037-8.
    1. Santos SD, Verveer PJ, Bastiaens PI. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol. 2007;9(3):324–330. doi: 10.1038/ncb1543.
    1. Kortum RL, Costanzo DL, Haferbier J, Schreiner SJ, Razidlo GL, Wu MH, Volle DJ, Mori T, Sakaue H, Chaika NV, Chaika OV, Lewis RE. The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates adipogenesis. Mol Cell Biol. 2005;25(17):7592–7604. doi: 10.1128/MCB.25.17.7592-7604.2005.
    1. Kortum RL, Lewis RE. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol. 2004;24(10):4407–4416. doi: 10.1128/MCB.24.10.4407-4416.2004.
    1. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, Gilbert D, Calder M, Pitt A, Kholodenko B, Kolch W. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal. 2010;3(153):ra90. doi: 10.1126/scisignal.2001212.
    1. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Blüthgen N. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol. 2011;7(1):489. doi: 10.1038/msb.2011.27.
    1. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5(3):173–183. doi: 10.1038/nrn1346.
    1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954. doi: 10.1038/nature00766.
    1. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63(14):3955–3957.
    1. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9(2):125–138. doi: 10.1006/scbi.1998.0083.
    1. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–13311. doi: 10.1073/pnas.0405220101.
    1. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 1999;18(8):2137–2148. doi: 10.1093/emboj/18.8.2137.
    1. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358–362. doi: 10.1038/nature04304.
    1. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell. 2005;20(6):963–969. doi: 10.1016/j.molcel.2005.10.022.
    1. Rushworth LK, Hindley AD, O’Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006;26(6):2262–2272. doi: 10.1128/MCB.26.6.2262-2272.2006.
    1. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209–221. doi: 10.1016/j.cell.2009.12.040.
    1. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–430. doi: 10.1038/nature08902.
    1. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci. 2009;106(11):4519–4524. doi: 10.1073/pnas.0900780106.
    1. Dultz LA, Dhar S, Ogilvie JB, Heller KS, Bar-Sagi D, Patel KN. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer. Surgery. 2013;154(6):1239–1245. doi: 10.1016/j.surg.2013.06.024.
    1. Lito P, Pratilas Christine A, Joseph Eric W, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong Wai L, Callahan Margaret K, Merghoub T, Wolchok Jedd D, de Stanchina E, Chandarlapaty S, Poulikakos Poulikos I, Fagin James A, Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22(5):668–682. doi: 10.1016/j.ccr.2012.10.009.
    1. Yao Z, Torres NM, Tao A, Gao YJ, Luo LS, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015;28(3):370–383. doi: 10.1016/j.ccell.2015.08.001.
    1. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5598–5611. doi: 10.1128/MCB.17.9.5598.
    1. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 1998;12(19):2997–3007. doi: 10.1101/gad.12.19.2997.
    1. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 2008;93(6):2194–2201. doi: 10.1210/jc.2007-2825.
    1. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008;68(22):9375–9383. doi: 10.1158/0008-5472.CAN-08-2223.
    1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819. doi: 10.1056/NEJMoa1002011.
    1. Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin A-M, Mazumdar J, Goodman VL, Trefzer U. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–3211. doi: 10.1200/JCO.2013.49.8691.
    1. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther. 2012;34(7):1474–1486. doi: 10.1016/j.clinthera.2012.06.009.
    1. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177–182. doi: 10.1097/CCO.0b013e3283436e8c.
    1. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci Signal. 2011;4(166):pe16. doi: 10.1126/scisignal.2001948.
    1. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401–1409. doi: 10.1038/nm.3392.
    1. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 2011;4(166):ra17. doi: 10.1126/scisignal.2001752.
    1. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013;3(3):338–349. doi: 10.1158/-12-0313.
    1. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee M-K, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977. doi: 10.1038/nature09626.
    1. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014;74(8):2340–2350. doi: 10.1158/0008-5472.CAN-13-2625.
    1. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118–122. doi: 10.1038/nature13121.
    1. Whittaker SR, Theurillat J-P, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3(3):350–362. doi: 10.1158/-12-0470.
    1. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong X-Q, Buchanan S, Henry JR, Starling JJ, Peng S-B. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012;287(33):28087–28098. doi: 10.1074/jbc.M112.377218.
    1. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853–4861. doi: 10.1158/0008-5472.CAN-07-6787.
    1. Shi H, Moriceau G, Kong X, Lee M-K, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724. doi: 10.1038/ncomms1727.
    1. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–4038. doi: 10.1200/JCO.2015.63.2497.
    1. Bollag G, Hirth P, Tsai J, Zhang JZ, Ibrahim PN, Cho HN, Spevak W, Zhang C, Zhang Y, Habets G, Burton E, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu XW, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599. doi: 10.1038/nature09454.
    1. Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R (2014) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer (Oxford, England: 1990) 50(2):406–410
    1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703. doi: 10.1056/NEJMoa1210093.
    1. Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell. 2015;28(3):384–398. doi: 10.1016/j.ccell.2015.08.002.
    1. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–695. doi: 10.1016/j.ccr.2010.11.023.
    1. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973. doi: 10.1371/journal.pone.0028973.
    1. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011;71(15):5067–5074. doi: 10.1158/0008-5472.CAN-11-0140.
    1. Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21(6):1313–1320. doi: 10.1158/1078-0432.CCR-14-2779.
    1. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657–667. doi: 10.1158/1078-0432.CCR-11-1446.
    1. Fattore L, Marra E, Pisanu M, Noto A, de Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi M, Ascierto P, Ciliberto G. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med. 2013;11(1):180. doi: 10.1186/1479-5876-11-180.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe